share_log

Exicure | 8-K: Current report

Exicure | 8-K: Current report

Exicure | 8-K：重大事件
美股sec公告 ·  06/25 16:26
Moomoo AI 已提取核心信息
Exicure, Inc., a biotechnology company listed on The Nasdaq Stock Market, received a notification of non-compliance from Nasdaq on June 20, 2024. The notice indicated that Exicure did not meet the minimum stockholders' equity requirement of $2,500,000 as stipulated by Nasdaq Listing Rule 5550(b)(1), which is essential for the continued listing of its common stock. In response to this deficiency, Exicure has announced its intention to address the issue during its pending appeal to the Nasdaq Hearings Panel, which is scheduled for July 9, 2024. The company is actively working to resolve the compliance issue and regain its standing with Nasdaq's listing requirements.
Exicure, Inc., a biotechnology company listed on The Nasdaq Stock Market, received a notification of non-compliance from Nasdaq on June 20, 2024. The notice indicated that Exicure did not meet the minimum stockholders' equity requirement of $2,500,000 as stipulated by Nasdaq Listing Rule 5550(b)(1), which is essential for the continued listing of its common stock. In response to this deficiency, Exicure has announced its intention to address the issue during its pending appeal to the Nasdaq Hearings Panel, which is scheduled for July 9, 2024. The company is actively working to resolve the compliance issue and regain its standing with Nasdaq's listing requirements.
生物技术公司Exicure， Inc.在纳斯达克股票市场上市。2024年6月20日，该公司收到了纳斯达克的不合规通知。该通知指出，Exicure没有达到纳斯达克上市规则5550(b)(1)规定的至少250万美元的股东权益要求，这是其普通股持续上市所必需的。对此不足，Exicure已经宣布其打算在即将到来的7月9日的纳斯达克听证会上解决问题。公司正在积极努力解决合规问题，恢复其与纳斯达克上市要求的地位。
生物技术公司Exicure， Inc.在纳斯达克股票市场上市。2024年6月20日，该公司收到了纳斯达克的不合规通知。该通知指出，Exicure没有达到纳斯达克上市规则5550(b)(1)规定的至少250万美元的股东权益要求，这是其普通股持续上市所必需的。对此不足，Exicure已经宣布其打算在即将到来的7月9日的纳斯达克听证会上解决问题。公司正在积极努力解决合规问题，恢复其与纳斯达克上市要求的地位。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息